N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide | 1426448-52-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
• 英文别名: N-(5-(5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl)-2-fluorophenyl)-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide；N-[5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl]-6-(5-methyl-1H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
• CAS: 1426448-52-3
• 化学式: C₂₃H₁₇F₃N₈O₂
• 分子量: 494.436
• InChiKey: XCRIYMJWHVQZPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  6-cyano-N-(5-(5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide 、 盐酸乙脒 在 caesium carbonate 、 copper(I) bromide 作用下， 以 二甲基亚砜 为溶剂， 生成 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-fluorophenyl}-6-(5-methyl-4H-1,2,4-triazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamide
  参考文献：
  名称：

  COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

  摘要：

  这项发明提供了化合物及其药物组合物，可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调激酶活性相关的疾病的方法。在某些实施例中，该发明提供了使用这些化合物治疗、改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα、PDGFRβ）激酶异常激活的疾病或紊乱的方法。

  公开号：

  US20130059846A1

文献信息

• Compounds and compositions as C-kit kinase inhibitors
  申请人：Yeh Vince

  公开号：US09199981B2

  公开（公告）日：2015-12-01

  The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

  本发明提供了化合物及其制药组合物，其作为蛋白激酶抑制剂是有用的，以及使用这些化合物的方法，以治疗、改善或预防与异常或非正常激酶活性相关的疾病或症状。在某些实施例中，本发明提供使用这些化合物的方法，以治疗、改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFRβ）激酶异常活化的疾病或疾病。
• COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP2751102A1

  公开（公告）日：2014-07-09
• US9199981B2
  申请人：——

  公开号：US9199981B2

  公开（公告）日：2015-12-01
• [EN] COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE C-KIT
  申请人：IRM LLC

  公开号：WO2013033070A1

  公开（公告）日：2013-03-07

  The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
• COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
  申请人：YEH Vince

  公开号：US20130059846A1

  公开（公告）日：2013-03-07

  The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

  这项发明提供了化合物及其药物组合物，可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调激酶活性相关的疾病的方法。在某些实施例中，该发明提供了使用这些化合物治疗、改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα、PDGFRβ）激酶异常激活的疾病或紊乱的方法。